Biotech’s Target Price Increased as Shares ‘Deeply Undervalued’

By The Life Science Report

Source: Streetwise Reports   11/15/2017

Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.

A Nov. 9 Wedbush research report indicated that Sierra Oncology Inc. (SRRA:NASDAQ) is expected to release initial clinical data from two Phase 1 studies of lead candidate SRA737, “a highly selective checkpoint kinase 1 inhibitor.” in Q1/18. “We think an update on SRA737’s safety profile will be meaningful, as well as on dosing strategies in the combination study,” reported analyst Driscoll. Interim data from those trials are anticipated in mid-2018.

Today, with those initial results due in the short term, Sierra Oncology’s shares are “deeply undervalued,” Driscoll noted. “We are raising our price target to $5 (from $4) to reflect our increased confidence in likely strong interim data in 2018 that could point to an accelerated path to approval.” The company is currently trading at around $2.02 per share.

In a recent gathering, key opinion leaders from Sierra Oncology’s recently formed DNA Damage Response Advisory Committee discussed the biopharmaceutical firm’s SRA737. They “highlighted the broad clinical potential” of the checkpoint inhibitor “across multiple tumor types as monotherapy and in combination with multiple potential agents,” such as immuno-oncology therapeutics, PARP inhibitors and chemotherapies, wrote Driscoll. The company’s therapeutics “target DNA-damage response pathways in cancer patients.”


Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






Because of the “strong clinical rationale for multiple therapeutic strategies” for SRA737 and it being further advanced, Sierra Oncology has chosen to focus on clarifying the development plan for that asset and defer submitting an investigational new drug application for its CDC7 inhibitor, SRA141, Driscoll said.

The research report also contained a brief summary of the company’s Q3/17 financials. Sierra Oncology posted a net loss of $10M ($0.19 per share), “above our estimate of ($0.21) on lower-than-expected operating expenses,” indicated Driscoll. At quarter’s end, it had $107.8M in cash and cash equivalents, which it “believes to be sufficient to fund ongoing operations through mid-2019.”

Wedbush has an Outperform rating on Sierra Oncology.

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you’ll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: SRRA:NASDAQ,
)